Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02696291 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects
A Phase 1 study, sponsored by Emergent BioSolutions.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT02696291 is a Phase 1 study that was terminated before completion, run by Emergent BioSolutions. The registered enrollment target is 7 participants.
The verdict
NCT02696291, a Phase 1 study, was terminated before completion, sponsored by Emergent BioSolutions.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and pharmacokinetics of UV-4B oral solution when administered to healthy subjects three times a day (TID) for 7 days.
Interventions
- DRUG UV-4B 30 mg oral solution
- DRUG UV-4B 75 mg oral solution
- DRUG UV-4B 150 mg oral solution
- DRUG UV-4B X mg (dose to be determined) oral solution
- DRUG UV-4B Y mg (dose to be determined) oral solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2016-05-27 |
| Est. Completion | 2017-03-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02696291
The ClinicalTrials.gov registry entry for NCT02696291 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emergent BioSolutions, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which UV-4B 30 mg oral solution is the first listed.
NCT02696291 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02696291 about?
NCT02696291 is a clinical study titled "Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects". The purpose of this study is to evaluate the safety and pharmacokinetics of UV-4B oral solution when administered to healthy subjects three times a day (TID) for 7 days.
What is the current status of trial NCT02696291?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2016-05-27. Estimated completion is 2017-03-02.
What interventions are being tested in trial NCT02696291?
The interventions under investigation include: UV-4B 30 mg oral solution (DRUG), UV-4B 75 mg oral solution (DRUG), UV-4B 150 mg oral solution (DRUG), UV-4B X mg (dose to be determined) oral solution (DRUG), UV-4B Y mg (dose to be determined) oral solution (DRUG).
Who is sponsoring clinical trial NCT02696291?
This trial is sponsored by Emergent BioSolutions, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.